Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ophthalmic emulsions containing prostaglandins

a technology of ophthalmic emulsions and prostaglandins, which is applied in the direction of elcosanoid active ingredients, antibacterial agents, immunological disorders, etc., can solve the problems of insufficiently satisfying proposed solutions to enhance the stability of prostaglandins, difficult to use bak or other quaternary ammonium as preservative or solubilising agent for prostaglandins in ophthalmic preparations, and improve the chemical stability of prostaglandin

Active Publication Date: 2012-09-25
SANTEN SAS
View PDF20 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text is discussing the need for ophthalmic prostaglandin products that are more efficient, stable, less toxic, and tolerable for patients. The goal is to create products that offer better chemical stability, physical stability over time, and good tolerability for patients.

Problems solved by technology

The problem encountered with prostaglandins, in particular with latanoprost, is that they are particularly chemically unstable.
However, the proposed solutions to enhance the stability of prostaglandins are not completely satisfactory.
Furthermore, use of BAK or other quaternary ammonium as preservative or solubilising agent for prostaglandins in ophthalmic preparations has been challenged, since C, Debbasch et al. in Investigative Ophthalmology & Visual Science, March 2001, Vol 42 no 3, demonstrated important toxicity of long term use of BAK and / or other quaternary ammoniums.
In cationic phospholipids colloids, the decrease in zeta potential evidences that the system is not completely chemically stable (Tamilvanan et al., STP Pharma Sciences 2001, 11:421-426) and in some cases could result in the physical destabilization of the formulation as reflected by the droplet size.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic emulsions containing prostaglandins

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0087]

EmulsionZ29EM002Z29EM003Z29EM005Z29EM007Composition   1% MCT   1% MCT0.02% BAK0.02% BAK 0.1% Lipoid 0.1% Tyloxapol  1% MCT  1% MCT 0.05% OA 0.05% OA0.16% Tyloxapol 0.3% Tyloxapol0.005% vit E0.005% vit E0.01% vit E0.01% vit E 0.25% Lutrol 0.25% Lutrol0.25% Lutrol 0.1% Lutrol 2.25% Glycerin 2.25% Glycerin2.25% Glycerin2.25% GlycerinWater to 100%Water to 100%Water to 100%Water to 100%Z29 0.005%Z29 0.005%Z29 0.005%Z29 0.005%Zeta potentialT0: 22.4T0: 21.8stress testT7: 24.1T7: 18.8T15: 19.8T15: 18.9Droplet sizeT0: 160T0: 212(nm)T7: 173T7: 225stress testT15: 185T15: 236EmulsionZ29EM008Z29EM011Composition0.02% BAK0.01% BAK  1% MCT  1% MCT 0.3% Tyloxapol 0.3% Tyloxapol 0.1% Lutrol 0.1% Lutrol2.25% Glycerin2.25% GlycerinWater to 100%Water to 100%Z29 0.005%Z29 0.005%ZetaT0: 20.6potentialT7: 18.5stress testT15: 16.2Droplet sizeT0: 201stress testT7: 212T15: 216

The oily phase components including 0.005% latanoprost (named Z29 in the Tables) were successively weighed in the same beaker and ...

example 2

Latanoprost Stability Improvement in Emulsion Compared to Commercial Product (Xalatan®)

[0091]The chemical stability of latanoprost within the emulsion was compared to the commercial product Xalatan® at 80° C. for 14 days.

[0092]Prostaglandin contents were analysed by an HPLC-UV method.

[0093]In emulsions according to the invention, latanoprost is chemically stabilized.

example 3

In Vivo Studies Demonstrating That Latanoprost emulsion is as Efficient as the Commercial Product (Xalatan®) in Reducing IOP (Intraocular Pressure)

Methods:

[0094]Eight adult female cynomolgus monkeys, each weighing 3-6 kg, in which glaucoma had been induced by diode laser photocoagulation of the mid-trabecular meshwork, were used in this study. Intraocular pressure (IOP) was measured at 0 hr (before drug administration) and then hourly until 6 hrs after drug administration for one baseline day, one vehicle-treated day, and treatment days 1,3, and 5 with 30 μl of Z29EM007 (similar to the emulsion described in Example 1) or 0.005% Latanoprost (Xalatan; Pharmarcia & Upjohn, Kalamazoo, Mich.).

[0095]The products were topically applied to the glaucomatous eye once daily for 5 consecutive days in a crossover design with a washout period at least 2 weeks between the two drugs.

Results:

[0096]Once daily administration of both Z29EM007 and Xalatan for 5 days significantly (p<0.005) reduced IOP f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

Cationic ophthalmic oil-in-water type emulsions, include colloid particles having an oily core surrounded by an interfacial film, the emulsion including at least one cationic agent and at least one non ionic surfactant, the oily core including a prostaglandin selected from the group comprising in particular latanoprost, unoprostone isopropyl, travoprost, bimatoprost, tafluprost, 8-isoprostaglandinE2, or a mixture thereof, for treating ocular hypertension and / or glaucoma. These emulsions have the property to increase the chemical stability of prostaglandins.

Description

FIELD OF THE INVENTION[0001]The present invention concerns ophthalmic cationic oil-in-water type emulsions containing prostaglandins.[0002]In the present invention, the term <<prostaglandin >> is indifferently used for prostaglandin, its precursors or analogs.[0003]The present invention is of particular interest for prostaglandin F2α analogs such as in particular latanoprost, unoprostone isopropyl, travoprost, bimatoprost, tafluprost, 8-isoprostaglandin E2.[0004]By <<ophthalmic >> it is meant an emulsion intended to be applied to the eye and which presents a pharmaceutical effect, preferably, it is topically applied.BACKGROUND OF THE INVENTION[0005]It is known to use prostaglandins in ophthalmic preparations in order to treat glaucoma.[0006]The problem encountered with prostaglandins, in particular with latanoprost, is that they are particularly chemically unstable.[0007]U.S. Pat. No. 6,011,062, U.S. Pat. No. 5,688,819, U.S. Pat. No. 5,849,792, U.S. Pat. No. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): C07C405/00A61P27/02A61K9/107
CPCA61K9/0048A61K31/5575A61K9/1075A61P27/02A61P27/04A61P27/06A61P27/14A61P29/00A61P31/00A61P31/04A61P31/10A61P31/12A61P35/00A61P37/06A61P43/00A61P9/10
Inventor PHILIPS, BETTYBAGUE, SEVERINERABINOVICH-GUILATT, LAURALAMBERT, GREGORY
Owner SANTEN SAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com